Sanofi is to pay $1bn up front to acquire privately held biotech Amunix Pharmaceuticals, Inc., which is developing products designed to overcome safety issues that have hampered the development of T-cell engager therapeutics in solid tumors. Amunix could also receive up to $225m upon reaching certain development milestones. The deal rides the wave of several bolt-on acquisitions made by the French big pharma group in 2021.
Mountain View, CA-headquartered Amunix specializes in developing T-cell engagers (TCEs) and cytokine therapies for cancer, having decided to build its...








